APPLY
VISIT
GIVE
Assistant Professor and Research Director
听
听
听
Education and Training
University Health Network, Toronto, Canada听 | Post-doctoral Fellowship | 2014-2019 | Multiple Myeloma Pathogenesis (drug resistance mechanisms) |
Utrecht University, Utrecht, the Netherlands | PhD | 7/2013 | Experimental Hematology |
High Institute for Education and Research in Transfusion Medicine, Tehran, Iran | M.Sc. | 9/2000 | Immunohematology/ Blood Banking |
Shahid Beheshti University of Medical Sciences, Tehran, Iran | B.Sc. | 6/1998 | Clinical Laboratory Science |
听
Teaching
CLS 307 Clinical Hematology
CLS 306 Clinical Immunology and Immunohematology
CLS 310 Coagulation and Hemostasis
CLS 441 Correlations in Clinical Chemistry
CLS 442 Correlations in Clinical Hematology/Urinalysis
CLS 443 Correlations in Clinical Immunohematology/Serology
CLS 492 Research Methods in Clinical Sciences
听
Research interests/activities听
Bone marrow mesenchymal stem cells (MSCs)
- Exploring their role in multiple myeloma (MM) resistance to immunotherapies
- Developing engineered MSCs with immune enhancing ability
Effects of omega-3 fatty acids (EPA and DHA) on CTL or NK cell-mediated cancer cell killing听
听
Google Scholar:
ORCiD:
听
Selected publications
- Abdi J, Nasr,P. Abnormalities of the primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, coagulation system, and bone marrow microenvironment. Frontiers in Hematology. 2025, March 02, 2025, vol.4. https://doi.org/10.3389/frhem.2025.1435193
- Abdi J, Redegeld F. Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin. PLoS One. 2025 Jan 28;20(1):e0310395. doi: 10.1371/journal.pone.0310395. PMID: 39874349; PMCID: PMC11774389.
- Immunophenotypic and functional characterization of Mesodermal Killer (MK) cells: a novel cell type and potential cellular therapy for cancer. Chapman, L, Abdi, J, Galvez-Peisl, S, Keating, A. Cytotherapy. 2020; 22 (5), Suppl. S121.
- Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells. Abdi J, Rastgoo N, Chen Y, Chen GA, Chang H. BMC Cancer. 2019;19(1):975.
- TLR pathway-miRNA interplay in mesenchymal stromal cells: Regulatory roles and therapeutic directions. Abdi J, Rashedi I, Keating A. Stem Cells. 2018 Nov;36(11):1655-1662. doi: 10.1002/stem.2902. Epub 2018 Oct 13
- Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by down-regulating RBPMS. Rastgoo N, Pourabdollah M, Abdi J, Reece D, Chang H. Leukemia 2018, DOI: 10.1038/s41375-018-0140-y
- miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Yang Y, Li F, Saha MN, Abdi J, Qiu L, Chang H. Clin Cancer Res. 2015 May 15;21(10):2399-411. doi: 10.1158/1078-0432.CCR-14-1437. Epub 2015 Feb 27.
- Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. Abdi J, Garssen J, Faber J, Redegeld FA. J Nutr Biochem. 2014 Dec;25(12):1254-62. doi: 10.1016/j.jnutbio.2014.06.013. Epub 2014 Sep 6.
- Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Abdi J, Chen G, Chang H. Oncotarget. 2013 Dec;4(12):2186-207. Review. Erratum in: Oncotarget. 2015 Apr 10;6(10):7364. Oncotarget. 2015 Apr 10;6(10):7364.
- Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells. Abdi J, Mutis T, Garssen J, Redegeld F. Blood Cancer J. 2013 May 31;3:e119. doi: 10.1038/bcj.2013.17.
听